Selecta Biosciences (SELB) Announces Earnings Results
Selecta Biosciences (NASDAQ:SELB) announced its quarterly earnings data on Friday. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.10, MarketWatch Earnings reports. The business had revenue of $0.90 million for the quarter.
SELB opened at $2.17 on Friday. Selecta Biosciences has a fifty-two week low of $1.41 and a fifty-two week high of $16.55. The stock has a market cap of $48.76 million, a PE ratio of -0.68 and a beta of 1.55.
In other news, Director Amir Nashat purchased 1,166,666 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was bought at an average cost of $1.50 per share, with a total value of $1,749,999.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 25.20% of the stock is owned by company insiders.
SELB has been the subject of a number of research reports. Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 10th. Needham & Company LLC cut their price target on Selecta Biosciences to $12.00 and set a “buy” rating for the company in a research note on Monday, January 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $7.00 price target on shares of Selecta Biosciences in a research note on Friday. Mizuho cut their price target on Selecta Biosciences to $4.00 and set a “buy” rating for the company in a research note on Monday, February 4th. Finally, ValuEngine downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $15.46.
COPYRIGHT VIOLATION NOTICE: “Selecta Biosciences (SELB) Announces Earnings Results” was first published by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.mareainformativa.com/news/2019/03/17/selecta-biosciences-selb-announces-earnings-results.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.